Literature DB >> 21481131

Associations between variants in the cyclooxygenase 2 enzyme gene (PTGS2) and development of benign prostate enlargement.

Jennifer L St Sauver1, Michael M Lieber, Susan L Slager, Debra J Jacobson, Michaela E McGree, Steven J Jacobsen.   

Abstract

OBJECTIVE: To determine if polymorphisms in the cyclooxygenase 2 (COX-2) enzyme gene (prostaglandin synthase 2; PTGS2) were associated with development of benign prostate enlargement (BPE), and whether associations were modified by use of nonsteroidal anti-inflammatory drugs (NSAIDs).
MATERIALS AND METHODS: Participants were men residing in Olmsted County, MN, who were between 40 and 79 years of age in 1990 (N= 356). Prostate volume was measured by transrectal ultrasound and men reported all the medications that they were taking at the time of the examination. Men were followed biennially for 16 years. Ten tagging single nucleotide polymorphisms (SNPs) in the PTGS2 gene were typed using the Illumina GoldenGate(TM) Assay. Associations between SNPs and development of BPE (volume >30 mL) were assessed by Cox proportional hazards models. Models were also stratified by NSAID use.
RESULTS: We observed significant associations between four polymorphisms in the PTGS2 gene and development of BPE (all P < 0.05). These associations were not observed among men who used NSAIDs.
CONCLUSION: Variants in the PTGS2 gene may increase the risk of prostate enlargement, but the increased risk may be minimized by use of NSAIDs.
© 2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21481131      PMCID: PMC3315350          DOI: 10.1111/j.1464-410X.2011.10161.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  31 in total

1.  Functional characterization of cyclooxygenase-2 polymorphisms.

Authors:  E Fritsche; S J Baek; L M King; D C Zeldin; T E Eling; D A Bell
Journal:  J Pharmacol Exp Ther       Date:  2001-11       Impact factor: 4.030

Review 2.  Benign prostatic hyperplasia: antecedents and natural history.

Authors:  H A Guess
Journal:  Epidemiol Rev       Date:  1992       Impact factor: 6.222

Review 3.  Identification of NSAID users at risk for gastrointestinal complications: a systematic review of current guidelines and consensus agreements.

Authors:  Merel M Tielemans; Ties Eikendal; Jan B M J Jansen; Martijn G H van Oijen
Journal:  Drug Saf       Date:  2010-06-01       Impact factor: 5.606

4.  Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response.

Authors:  Anastasia Papafili; Michael R Hill; David J Brull; Robin J McAnulty; Richard P Marshall; Steve E Humphries; Geoffrey J Laurent
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-10-01       Impact factor: 8.311

5.  The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.

Authors:  John D McConnell; Claus G Roehrborn; Oliver M Bautista; Gerald L Andriole; Christopher M Dixon; John W Kusek; Herbert Lepor; Kevin T McVary; Leroy M Nyberg; Harry S Clarke; E David Crawford; Ananias Diokno; John P Foley; Harris E Foster; Stephen C Jacobs; Steven A Kaplan; Karl J Kreder; Michael M Lieber; M Scott Lucia; Gary J Miller; Mani Menon; Douglas F Milam; Joe W Ramsdell; Noah S Schenkman; Kevin M Slawin; Joseph A Smith
Journal:  N Engl J Med       Date:  2003-12-18       Impact factor: 91.245

6.  Relationship between prostate specific antigen, prostate volume and age in the benign prostate.

Authors:  G N Collins; R J Lee; G B McKelvie; A C Rogers; M Hehir
Journal:  Br J Urol       Date:  1993-04

7.  Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium.

Authors:  Wanzhong Wang; Anders Bergh; Jan-Erik Damber
Journal:  Prostate       Date:  2004-09-15       Impact factor: 4.104

8.  Patterns of inflammation in prostatic hyperplasia: a histologic and bacteriologic study.

Authors:  P W Kohnen; G W Drach
Journal:  J Urol       Date:  1979-06       Impact factor: 7.450

9.  Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis.

Authors:  Franco Di Silverio; Vincenzo Gentile; Anna De Matteis; Gianna Mariotti; Voria Giuseppe; Pastore Antonio Luigi; Alessandro Sciarra
Journal:  Eur Urol       Date:  2003-02       Impact factor: 20.096

Review 10.  Clinical implications of COX-1 and/or COX-2 inhibition for the distal gastrointestinal tract.

Authors:  Angel Lanas; Julián Panés; Josep M Piqué
Journal:  Curr Pharm Des       Date:  2003       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.